346 related articles for article (PubMed ID: 22909934)
1. Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.
Beck A; Lambert J; Sun M; Lin K
MAbs; 2012; 4(6):637-47. PubMed ID: 22909934
[TBL] [Abstract][Full Text] [Related]
2. World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
Beck A; Senter P; Chari R
MAbs; 2011; 3(4):331-7. PubMed ID: 21691144
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
4. Antibody-drug conjugates: present and future.
Beck A; Reichert JM
MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
[TBL] [Abstract][Full Text] [Related]
5. Site-specific antibody drug conjugates for cancer therapy.
Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
[TBL] [Abstract][Full Text] [Related]
6. World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.
Klinguer-Hamour C; Strop P; Shah DK; Ducry L; Xu A; Beck A
MAbs; 2014; 6(1):18-29. PubMed ID: 24423618
[TBL] [Abstract][Full Text] [Related]
7. American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.
Thudium K; Bilic S; Leipold D; Mallet W; Kaur S; Meibohm B; Erickson H; Tibbitts J; Zhao H; Gupta M
MAbs; 2013; 5(1):5-12. PubMed ID: 23255090
[TBL] [Abstract][Full Text] [Related]
8. New developments for antibody-drug conjugate-based therapeutic approaches.
de Goeij BE; Lambert JM
Curr Opin Immunol; 2016 Jun; 40():14-23. PubMed ID: 26963132
[TBL] [Abstract][Full Text] [Related]
9. Third-generation antibody drug conjugates for cancer therapy--a balancing act.
Vankemmelbeke M; Durrant L
Ther Deliv; 2016; 7(3):141-4. PubMed ID: 26893243
[No Abstract] [Full Text] [Related]
10. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.
Janthur WD; Cantoni N; Mamot C
Int J Mol Sci; 2012 Nov; 13(12):16020-45. PubMed ID: 23443108
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
[TBL] [Abstract][Full Text] [Related]
12. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
[TBL] [Abstract][Full Text] [Related]
13. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.
Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR
J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794
[TBL] [Abstract][Full Text] [Related]
14. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates.
Zolot RS; Basu S; Million RP
Nat Rev Drug Discov; 2013 Apr; 12(4):259-60. PubMed ID: 23535930
[No Abstract] [Full Text] [Related]
16. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
17. Strategies and challenges for the next generation of antibody-drug conjugates.
Beck A; Goetsch L; Dumontet C; Corvaïa N
Nat Rev Drug Discov; 2017 May; 16(5):315-337. PubMed ID: 28303026
[TBL] [Abstract][Full Text] [Related]
18. 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.
Beck A; Wurch T; Reichert JM
MAbs; 2011; 3(2):111-32. PubMed ID: 21441785
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
20. ADME of antibody-maytansinoid conjugates.
Erickson HK; Lambert JM
AAPS J; 2012 Dec; 14(4):799-805. PubMed ID: 22875610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]